Literature DB >> 8366100

Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I.

F D Ferreira1, K Hoffmann-Sommergruber, H Breiteneder, K Pettenburger, C Ebner, W Sommergruber, R Steiner, B Bohle, W R Sperr, P Valent.   

Abstract

Pollen from trees of the order Fagales (e.g. birch, alder, hazel, oak, and hornbeam) are a major cause of Type I allergies observed in early spring. Previously, we reported the cloning and sequencing of Bet v I, the major birch pollen allergen, which showed high sequence similarities to a family of plant pathogen-activated genes (Breiteneder, H., Pettenburger, K., Bito, A., Valenta, R., Kraft, D., Rumpold, H., Scheiner, O., and Breitenbach, M. (1989) EMBO J. 8, 1935-1938). Here, we present the results on the expression, purification, and characterization of recombinant Bet v I produced in Escherichia coli as fusion and non-fusion protein, respectively. The purified recombinant proteins were analyzed to verify purity and structural integrity, and their immunological properties were compared to those of Bet v I isolated from birch pollen (natural Bet v I). Immunoblot analyses showed that the recombinant proteins are specifically recognized by monoclonal antibodies raised against natural Bet v I as well as by IgE from birch pollen-allergic patients. However, enzyme-linked immunosorbent assays revealed a decreased IgE-binding activity of the recombinant fusion Bet v I compared to the non-fusion and natural Bet v I proteins, which probably results from conformational changes due to the fusion tail. Recombinant non-fusion Bet v I was equivalent to natural Bet v I with respect to IgE-binding properties, the ability to induce in vitro proliferation of allergen-specific T-cell clones, and the ability to release histamine from basophils derived from birch pollen-allergic patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8366100

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Authors:  S Vrtala; K Hirtenlehner; L Vangelista; A Pastore; H G Eichler; W R Sperr; P Valent; C Ebner; D Kraft; R Valenta
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

2.  A pollen allergen-encoding gene is expressed in wheat ovaries.

Authors:  H J Balzer; L Borisiuk; H M Meyer; F Matzk; H Bäumlein
Journal:  Plant Mol Biol       Date:  1996-11       Impact factor: 4.076

3.  A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.

Authors:  Katharina Marth; Isabella Breyer; Margarete Focke-Tejkl; Katharina Blatt; Mohamed H Shamji; Janice Layhadi; Anna Gieras; Ines Swoboda; Domen Zafred; Walter Keller; Peter Valent; Stephen R Durham; Rudolf Valenta
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

4.  Diversity of TCRAV and TCRBV sequences used by human T-cell clones specific for a minimal epitope of Bet v 1, the major birch pollen allergen.

Authors:  H Breiteneder; O Scheiner; R Hajek; W Hulla; R Hüttinger; G Fischer; D Kraft; C Ebner
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Infection with Rhinovirus Facilitates Allergen Penetration Across a Respiratory Epithelial Cell Layer.

Authors:  Katharina Gangl; Eva E Waltl; Helga Vetr; Clarissa R Cabauatan; Katarzyna Niespodziana; Rudolf Valenta; Verena Niederberger
Journal:  Int Arch Allergy Immunol       Date:  2015-05-13       Impact factor: 2.749

6.  Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome.

Authors:  Matthias Egger; Alexander Jürets; Michael Wallner; Peter Briza; Silke Ruzek; Stefan Hainzl; Ulrike Pichler; Claudia Kitzmüller; Barbara Bohle; Christian G Huber; Fátima Ferreira
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

7.  Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.

Authors:  F Ferreira; K Hirtenlehner; A Jilek; J Godnik-Cvar; H Breiteneder; R Grimm; K Hoffmann-Sommergruber; O Scheiner; D Kraft; M Breitenbach; H J Rheinberger; C Ebner
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

8.  Ligand Recognition of the Major Birch Pollen Allergen Bet v 1 is Isoform Dependent.

Authors:  Christian Seutter von Loetzen; Thessa Jacob; Olivia Hartl-Spiegelhauer; Lothar Vogel; Dirk Schiller; Cornelia Spörlein-Güttler; Rainer Schobert; Stefan Vieths; Maximilian Johannes Hartl; Paul Rösch
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

9.  The influence of recombinant production on the immunologic behavior of birch pollen isoallergens.

Authors:  Michael Wallner; Martin Himly; Angela Neubauer; Anja Erler; Michael Hauser; Claudia Asam; Sonja Mutschlechner; Christof Ebner; Peter Briza; Fatima Ferreira
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

10.  Identification and in silico bioinformatics analysis of PR10 proteins in cashew nut.

Authors:  Shanna Bastiaan-Net; Maria C Pina-Pérez; Bas J W Dekkers; Adrie H Westphal; Antoine H P America; Renata M C Ariëns; Nicolette W de Jong; Harry J Wichers; Jurriaan J Mes
Journal:  Protein Sci       Date:  2020-05-16       Impact factor: 6.725

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.